Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 200 Day Moving Average of $11.80

Fennec Pharmaceuticals Inc. (TSE:FRX)’s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$11.80 and traded as low as C$9.20. Fennec Pharmaceuticals shares last traded at C$9.23, with a volume of 1,101 shares changing hands.

Fennec Pharmaceuticals Trading Up 1.7 %

The company has a quick ratio of 10.17, a current ratio of 6.93 and a debt-to-equity ratio of 1,040.68. The firm has a market cap of C$252.16 million, a price-to-earnings ratio of 184.60 and a beta of 0.46. The business’s fifty day moving average is C$8.98 and its two-hundred day moving average is C$11.78.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.67 by C($0.11). The company had revenue of C$34.21 million during the quarter, compared to analyst estimates of C$14.19 million. Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 1,005.59%. Equities analysts anticipate that Fennec Pharmaceuticals Inc. will post 1.1958225 earnings per share for the current fiscal year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.